Introduction: This study evaluates the therapeutic outcomes for laparoscopic
Introduction
Acute cholecystitis (AC) occurs in 15% of all patients with symptomatic cholecystitis (1) . At present, the international guidelines on AC, the 2013 Tokyo Guidelines (TG13) (2) (3) (4) , are being used globally to define the basic criteria for the management of AC (5) (6) (7) (8) . Based on several randomized controlled trials and meta-analyses (9) (10) (11) (12) (13) (14) , the TG13 recommended early laparoscopic cholecystectomy (ELC) within 72 h from symptom onset as the basic therapeutic strategy for AC, especially in mild (grade I) AC. Patients with symptoms for more than 72 h and in whom the degree of acute inflammation is likely to be associated with increased difficulty in performing cholecystectomy were defined as moderate (grade II) AC. Gallbladder (GB) drainage was recommended in these cases as first-line therapy, followed by delayed laparoscopic cholecystectomy (DLC) 2-3 months later, after patients' condition had improved (3, 15) . However, if advanced laparoscopic surgical techniques are available, ELC may be performed on patients with moderate AC (4) .
The "golden 72-h rule" has been proposed as appropriate for laparoscopic cholecystectomy (LC) during the acute phase. After 72 h, complication rates and conversion to open surgery increase during LC (16, 17) . Several randomized controlled trials, meta-analysis, and population-based cohort studies have shown that ELC, when compared with DLC, was associated with a shorter hospital stay and similar rate of conversion to open surgery (9) (10) (11) (18) (19) (20) . However, these studies were criticized for multiple reasons. Firstly, the time frame for ELC varied from within 24 h to 7 days. Therefore, the optimal timing for ELC for AC remains unclear. Secondly, although the TG13 recommended early surgery within 72 h of symptom onset, almost all studies used the duration from presentation to surgery, rather than the duration from symptom onset to surgery, for evaluation. Thirdly, these studies did not evaluate comorbidities, inflammatory findings, local inflammation, severity, and the correlation between surgeon's experience and operative outcomes. Also, the patients evaluated were not matched according to condition and inflammatory status.
Despite this evidence and guideline support for ELC, DLC has remained the preference of many surgeons. In some countries, the rate of performance of ELC for AC ranged from 11% to 41.7% (21) (22) (23) (24) . ELC within 72 h of symptom onset may not be possible for many reasons such as operative room availability, surgeon availability, and patient's condition. Therefore, in the present study, we analyzed the therapeutic outcomes of propensity-matched patients with AC based on the duration from symptom onset to LC.
Materials and Methods
The medical records of patients who underwent LC for AC in our department between April 2005 and September 2015 were retrospectively reviewed with the approval of our hospital's ethics review board. All patients preoperatively gave written informed consent to undergo LC. Patients with common bile duct stones were excluded from the analysis. A definitive diagnosis of AC and its severity classification were based on the TG13 criteria (15) .
Our basic therapeutic strategy has been previously reported (25) . Briefly, ELC is performed as soon as possible for every AC patients, regardless of the time from onset, provided that general anesthesia can be administered safely. In some cases, we perform GB drainage when LC cannot be performed on the day of presentation because of the patient's unstable condition or unavailable operating rooms or surgeons. In this study, eight surgeons performed the LC procedures, in the presence of at least one board-certified surgeon. The surgeons who performed the LC procedures had a median of 14 years of experience (range, 5-25 years) for median number of 20 AC cases (range, 4-54 cases).
The TG13 recommended early surgery within 72 h from symptom onset. Therefore, we applied one threshold: 72 h. However, in published reports, the time frame for early surgery varied from 24 h to 7 days (9) (10) (11) (18) (19) (20) . Therefore, we also applied the 7-day threshold, which was the longest duration from onset to surgery. Patient characteristics and operative outcomes were compared between the ≤72 h and >72 h groups and between the ≤7 days and ≥8 days groups. After analysis, we used propensity score matching (PSM) to account for selection bias. Propensity scores were matched using a caliper width of 0.25 multiplied by the standard deviation of values that were calculated by a logistic regression model. A propensity score was estimated using 13 relevant variables related to patient demographics (age, gender, BMI, duration from symptom onset to presentation, Charlson comorbidity index (26) , and body temperature), examination findings (white blood cell count, Creactive protein level, total bilirubin level, marked local inflammation, and severity grade), and therapeutic factors (preoperative GB drainage and surgeon's experience). Marked local inflammation was defined according to TG13 as gangrenous cholecystitis, pericholecystic abscess, hepatic abscess, biliary peritonitis, and emphysematous cholecystitis.
Statistical analysis was performed using Fisher's exact test and χ 2 test for categorical data and the Mann-Whitney U-test for continuous data. Categorical variables were described as numbers, and continuous variables were described as median and ranges. A P-value of <0.05 was considered statistically significant. All statistical analyses were performed using R software version 3.2.3 (R Development Core Team, http://www.r-project.org).
Results
There were 224 patients with AC included in this study population; 160 were men and 64 were women. The median age was 64 years (range, 26-91 years). With regard to case severity, there were 120 mild (grade I) cases (53.5%), 102 cases moderate (grade II) (45.5%), and 2 severe (grade III) cases (1.0%). The median duration from symptom onset to presentation was 24 h (range, 1-336 h), and the median duration from symptom onset to LC was 3 days (range, 0-31 days). The median length of preoperative hospital stay was 1 day (range, 0-30 days). Antithrombotic agents were taken by 48 patients (21.4%). Preoperative GB drainage was performed for 73 patients (32.6%). Intraoperative bile duct injury occurred in one patient (0.4%). Conversion to open surgery was necessary in 16 patients (7.1%). Among the surgeons, there was no significant difference in the rate of conversion to open surgery (range, 0%-15.0%). Postoperative complications occurred in 10 patients (4.5%); these included wound infection in five; intra-abdominal abscess in two; pseudomembranous colitis in two; and small bowel injury, bile leakage, and heart failure in one patient each. There was no mortality in this study.
Timing of surgery from symptom onset (≤72 h vs >72 h) before PSM
The correlation of patient characteristics according to the time from symptom onset to surgery between ≤72 h (n = 116, 51.8%) and >72 h (n = 108, 48.2%) is shown in Table 1 . Compared with the >72 h group, the ≤72 h group was significantly younger and had a shorter duration from symptom onset to presentation, fewer comorbidities, and less inflammation, as indicated by body temperature, C-reactive protein value, and TG13 severity grades. The ≤72 h group comprised 66.4% mild, 32.7% moderate, and 0.9% severe AC patients, whereas the >72 h group comprised 39.8% mild, 59.3% moderate, and 0.9% severe AC patients. Need for preoperative GB drainage and duration from symptom onset to surgery revealed significant differences between these groups. Duration of surgery, postoperative hospital stay, and total length of hospital stay were significantly shorter in the ≤72 h group. Intraoperative blood loss, conversion to open surgery, intraoperative bile duct injury, and postoperative complications showed no significant differences between the groups.
Timing of surgery from symptom onset (≤7 days vs ≥8 days) before PSM The correlation of patient characteristics according to the time from symptom onset to surgery between ≤7 days (n = 177, 79.0%) and ≥8 days (n = 47, 21.0%) is shown in Table 2 . Compared with the ≥8 days group, the patients in the ≤7 days group were significantly younger, had a shorter time from symptom onset to presentation, and had fewer comorbidities. Need for preoperative GB drainage and duration from symptom onset to surgery revealed significant differences. Duration of surgery, postoperative hospital stay, and total length of stay were significantly shorter in the ≤7 days group. Intraoperative blood loss, conversion to open surgery, intraoperative bile duct injury, and postoperative complications showed no significant differences between the groups. PSM, propensity score matching; T-Bil, total bilirubin; TG13, 2013 Tokyo Guideline. Categorical variables are described as numbers, and continuous variables are described as median and ranges.
Timing of surgery from symptom onset (≤72 h vs >72 h) after PSM PSM of the 13 factors created 82 distinct pairs of patients who were compared based on the time from symptom onset to LC (≤72 h vs >72 h). After PSM, all patient and surgeon characteristics were well balanced (Table 3) . Except for time from symptom onset to surgery, the variables did not significantly differ between the groups.
Timing of surgery from symptom onset (≤7 days vs ≥8 days) after PSM PSM of the 13 factors created 58 distinct pairs of patients who were compared based on the time from symptom onset to LC (≤7 days vs ≥8 days). After PSM, all patient and surgeon characteristics were well balanced (Table 4) . Except for time from symptom onset to surgery and total length of hospital stay, the variables did not significantly differ between the groups.
Discussion
The present study used PSM analysis to evaluate the therapeutic outcomes of ELC, which we defined as LC ≤72 h or ≤7 days from symptom onset to surgery. Before PSM, only 51.8% of patients underwent LC within 72 h from symptom onset. In contrast, 79.0% of patients underwent LC within 7 days of symptom onset. The patients in the early surgery groups were significantly younger, had fewer comorbidities, and had a shorter time from symptom onset to presentation. In terms of operative outcomes, they had a significantly shorter surgery, postoperative hospital stay, and total length of stay. However, the other operative outcomes, including intraoperative blood loss, conversion to open surgery, intraoperative bile duct injury, and postoperative complications, revealed no significant differences between the groups. Initially, when surgeons were less experienced in laparoscopic techniques and were hesitant to operate on inflamed tissues, acute cholecystitis was considered a contraindication for LC (27) . However, recent population-based analyses of appropriate timing from presentation to surgery showed significantly fewer conversions to open surgery (18) , major bile duct injuries (19) , and postoperative complications (18, 20) , as well as less mortality with ELC than with DLC (20) . Additionally, these studies showed shorter total length of hospital stay and lower medical costs (18, 20) . They also emphasized that LC should be performed as soon as possible after presentation, particularly within 48 h (18, 20) . A recent meta-analysis of 15 randomized controlled trials (N = 1625) that compared ELC (within 7 days) with DLC (at least one week after symptoms had subsided) showed that ELC was associated with significantly lower hospital costs, lower risk of postoperative wound infection, and shorter length of hospital stay, but ELC required more surgical time (28) . Mortality, bile duct injury, bile leakage, conversion to open surgery, and overall postoperative complications were not significantly different between the groups. In the present study, approximately 80% of the patients underwent LC within 7 days. The duration of surgery was significantly shorter in the ≤7 days group than in the ≥8 days group. Other operative outcomes showed no significant differences between the two groups. LC as soon as possible after presentation has been the basic therapeutic strategy in our department, as long as the patient can be safely placed under general anesthesia (25) . In the present study, the median preoperative hospital stay was 1 day. Approximately half of the study population underwent LC within 72 h of onset of AC symptoms. Therefore, the duration from symptom onset to surgery was probably influenced by the duration from symptom onset to presentation. Indeed, the duration from symptom onset to presentation was significantly shorter in the ≤72 h group. Furthermore, duration from symptom onset to presentation was subjective and depended on each patient's threshold. TG13 defined moderate AC as the consistent presence of symptoms for more than 72 h and recommended GB drainage as the initial therapy for these patients (3) . As such, particularly in Japan, GB drainage has generally been preferred as the first-line therapy for moderate AC patients, followed by DLC (29, 30) . PSM, propensity score matching; T-Bil, total bilirubin; TG13, 2013 Tokyo Guideline. Categorical variables are described as numbers, and continuous variables are described as median and ranges.
For large population-based studies, measurement of the timing of surgery may be more accurate if it is based on the time from presentation rather than from symptom onset. In our previous study, the duration of ≥72 h from symptom onset to presentation was a significant risk factor for conversion to open surgery (6) . In the present study, data from the previous study were excluded because of the lack of details. According to the new data from this study, rates of conversion to open surgery did not significantly differ between the ≤72 h and ≥72 h groups, even before PSM. Increased experience in performing LC for AC may have also contributed to the results of the present study.
PSM analysis is increasingly used in retrospective cohorts to reduce the impact of treatment-selection bias when dealing with non-randomized control and observational data. This type of evaluation has been proven to decrease selection bias in retrospective studies and allows for comparison of different therapeutic strategies. Based on our analyses after PSM, ELC at an experienced laparoscopic center could be performed for moderate AC patients, including those who have been symptomatic for more than 72 h, according to TG13.
Several limitations existed in our study. It was retrospective in nature and included a relatively small number of patients. Also, although PSM was used to reduce potential bias, the number of patients further decreased after PSM. Moreover, the time from symptom onset to presentation was subjective and may have confounded the accurate time of symptom onset. Finally, our institute had sufficient experience in managing AC and treating it laparoscopically. Therefore, our therapeutic strategy may not be applicable to centers with less experience with LC for AC.
In conclusion, performing LC as soon as possible after presentation, regardless of the time from symptom onset, is a safe and beneficial therapeutic strategy for AC patients in centers with sufficient laparoscopic experience.
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